jRCT2080223060已完成2 期
Safety study of NaPPS in pediatric patients with mucopolysaccharidosis type VI
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Non-randomized, open-label, dose-escalation study followed by continuous administration study
入排标准
- 年龄范围
- 6age old over 至 14age old under（—）
- 性别
- All
入选标准
- •(1) Patients who are confirmly diagnosed with Mucopolysaccharidosis type VI and have assessable symptoms of cartilage and bone.
- •(2) Patients who are able to explain their own condition or to show their own intention.
- •(3) Patients who are able to walk for 6 minutes continuously.
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Safety study of NaPPS in pediatric patients with mucopolysaccharidosis type VImucopolysaccharidosis type VIJPRN-jRCT2080223060ReqMed Company, Ltd.2
进行中（未招募）
不适用
Study of efficacy and safety of NaPPS in patients with knee osteoarthritis (PPS-O-201)knee osteoarthritisjRCT2071210131ReqMed Company, Ltd.90
尚未招募
3 期
Assessment of praziquantel medication for children living in areas where schistosomiasis is common in Bahia and SergipeRBR-86kcy37Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)
已完成
不适用
Tolerance and safety study of a new paediatric peptide feedISRCTN48462333umico Research B.V. (Netherlands)24
尚未招募
1 期
euroEPO-Stroke. Phase I-IIStrokeRPCEC00000185Center of Molecular Immunology, CIMAB